Fangfang Bi
- Cancer Research top 5%
- Cancer-related molecular mechanisms research 9
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment 7
- Geriatrics and Gerontology top 10%
-
- RNA modifications and cancer 12
- Epigenetics and DNA Methylation 8
-
- PARP inhibition in cancer therapy 5
-
- Endometrial and Cervical Cancer Treatments 5
-
- BRCA gene mutations in cancer 4
-
- Reproductive Biology and Fertility 4
- Co-authors
- Qing YangDa LiTianshui SunZhuonan LiuYing ChenYuanyuan AnYiming ZhouJi-Min Cao
- Journals
- SHILAP Revista de lepidopterología (1 paper)Scientific Reports (1 paper)Molecular Cancer (2 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Fangfang Bi
47 papers receiving 963 citations
Peers
Comparison fields: 5 of 82
- Cancer Research 347
- Reproductive Medicine 167
- Geriatrics and Gerontology 34
- Molecular Biology 560
- Oncology 194
Countries citing papers authored by Fangfang Bi
This map shows the geographic impact of Fangfang Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangfang Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangfang Bi more than expected).
Fields of papers citing papers by Fangfang Bi
This network shows the impact of papers produced by Fangfang Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangfang Bi. The network helps show where Fangfang Bi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fangfang Bi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2023 | 5 | |
| 3 | 2023 | 12 | |
| 4 | 2022 | 6 | |
| 5 | 2021 | 8 | |
| 6 | 2021 | 8 | |
| 7 | 2021 | 36 | |
| 8 | 2021 | 22 | |
| 9 | 2021 | 2 | |
| 10 | Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling | 2020 | 1 |
| 11 | 2020 | 64 | |
| 12 | 2019 | 9 | |
| 13 | 2017 | 77 | |
| 14 | 2015 | 15 | |
| 15 | 2014 | 31 | |
| 16 | 2014 | 24 | |
| 17 | 2013 | 23 | |
| 18 | 2013 | 19 | |
| 19 | 2013 | 11 | |
| 20 | 2012 | 8 |
About Fangfang Bi
Fangfang Bi is a scholar working on Reproductive Medicine, Cancer Research and Obstetrics and Gynecology, having authored 48 papers that have together received 984 indexed citations. Recurring topics across this work include RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (9 papers), Epigenetics and DNA Methylation (8 papers), Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers), Endometrial and Cervical Cancer Treatments (5 papers), BRCA gene mutations in cancer (4 papers) and Reproductive Biology and Fertility (4 papers). The work is most often cited by research in Cancer Research (347 citations), Reproductive Medicine (167 citations) and Geriatrics and Gerontology (34 citations). Fangfang Bi has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Qing Yang, Da Li, Tianshui Sun, Zhuonan Liu, Qing Yang, Ying Chen, Yuanyuan An, Yiming Zhou, Ji-Min Cao and Ying Chen. Their work appears in journals such as SHILAP Revista de lepidopterología, Scientific Reports and Molecular Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.